Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

References

• Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune response. Immunol Rev 2008; 225:272 - 83; http://dx.doi.org/10.1111/j.1600-065X.2008.00671.x; PMID: 18837788
   PubMed Web of Science ®Google Scholar
• Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011; 9:451 - 62; http://dx.doi.org/10.1016/j.chom.2011.05.008; PMID: 21669394
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J 2009; 8:312; http://dx.doi.org/10.1186/1475-2875-8-312; PMID: 20042088
   PubMed Web of Science ®Google Scholar
• Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines 2011; 10:355 - 64; http://dx.doi.org/10.1586/erv.11.7; PMID: 21434803
   PubMed Web of Science ®Google Scholar
• Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 2011; 6:e24586; http://dx.doi.org/10.1371/journal.pone.0024586; PMID: 22003383
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012; 20:2355 - 68; http://dx.doi.org/10.1038/mt.2012.223; PMID: 23089736
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 2005; 102:4836 - 41; http://dx.doi.org/10.1073/pnas.0406381102; PMID: 15781866
   PubMed Web of Science ®Google Scholar
• Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A 2001; 98:10817 - 22; http://dx.doi.org/10.1073/pnas.181123498; PMID: 11526203
   PubMed Web of Science ®Google Scholar
• Wang R, Doolan DL, Charoenvit Y, Hedstrom RC, Gardner MJ, Hobart P, et al. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun 1998; 66:4193 - 202; PMID: 9712767
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010; 78:145 - 53; http://dx.doi.org/10.1128/IAI.00740-09; PMID: 19858306
   PubMed Web of Science ®Google Scholar
• Jiang G, Shi M, Conteh S, Richie N, Banania G, Geneshan H, et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS One 2009; 4:e6559; http://dx.doi.org/10.1371/journal.pone.0006559; PMID: 19668343
   PubMed Web of Science ®Google Scholar
• Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A 1994; 91:9866 - 70; http://dx.doi.org/10.1073/pnas.91.21.9866; PMID: 7937907
   PubMed Web of Science ®Google Scholar
• Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18:1893 - 901; http://dx.doi.org/10.1016/S0264-410X(99)00407-7; PMID: 10699338
   PubMed Web of Science ®Google Scholar
• Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, Osinowo O, et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002; 13:1551 - 60; http://dx.doi.org/10.1089/10430340260201644; PMID: 12228010
   PubMed Web of Science ®Google Scholar
• Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, et al. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother 2012; 8:1564 - 84; http://dx.doi.org/10.4161/hv.22129; PMID: 23151451
   PubMed Web of Science ®Google Scholar
• Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS ONE 2013; 8:e55571; PMID: 23457473
   PubMed Web of Science ®Google Scholar
• Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 2011; 6:e25868; http://dx.doi.org/10.1371/journal.pone.0025868; PMID: 22003411
   PubMed Web of Science ®Google Scholar
• Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003; 41:5046 - 52; http://dx.doi.org/10.1128/JCM.41.11.5046-5052.2003; PMID: 14605137
   PubMed Web of Science ®Google Scholar
• Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, Quakyi IA, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986; 35:66 - 8; PMID: 3511753
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O’Hara GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 2012; 7:e31208; http://dx.doi.org/10.1371/journal.pone.0031208; PMID: 22363582
   PubMed Web of Science ®Google Scholar
• Good MF, Quakyi IA, Saul A, Berzofsky JA, Carter R, Miller LH. Human T clones reactive to the sexual stages of Plasmodium falciparum malaria. High frequency of gamete-reactive T cells in peripheral blood from nonexposed donors. J Immunol 1987; 138:306 - 11; PMID: 2431058
   PubMed Web of Science ®Google Scholar
• Fell AH, Silins SL, Baumgarth N, Good MF. Plasmodium falciparum-specific T cell clones from non-exposed and exposed donors are highly diverse in TCR beta chain V segment usage. Int Immunol 1996; 8:1877 - 87; http://dx.doi.org/10.1093/intimm/8.12.1877; PMID: 8982772
   PubMed Web of Science ®Google Scholar
• Holst PJ, Ørskov C, Thomsen AR, Christensen JP. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 2010; 184:4431 - 9; http://dx.doi.org/10.4049/jimmunol.0900537; PMID: 20212099
   PubMed Web of Science ®Google Scholar
• De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, et al, National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 2011; 187:3391 - 401; http://dx.doi.org/10.4049/jimmunol.1101421; PMID: 21844392
   PubMed Web of Science ®Google Scholar
• Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS, et al. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells. J Immunother 2010; 33:510 - 22; http://dx.doi.org/10.1097/CJI.0b013e3181d75cef; PMID: 20463596
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011; 187:1347 - 57; http://dx.doi.org/10.4049/jimmunol.1100302; PMID: 21715686
   PubMed Web of Science ®Google Scholar
• Jobe O, Donofrio G, Sun G, Liepinsh D, Schwenk R, Krzych U. Immunization with radiation-attenuated Plasmodium berghei sporozoites induces liver cCD8alpha+DC that activate CD8+T cells against liver-stage malaria. PLoS One 2009; 4:e5075; http://dx.doi.org/10.1371/journal.pone.0005075; PMID: 19347042
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247 - 58; http://dx.doi.org/10.1038/nri2274; PMID: 18323851
   PubMed Web of Science ®Google Scholar
• Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008; 371:923 - 31; http://dx.doi.org/10.1016/S0140-6736(08)60418-3; PMID: 18342687
   PubMed Web of Science ®Google Scholar
• Harro CD, Robertson MN, Lally MA, O’Neill LD, Edupuganti S, Goepfert PA, et al, Merck V520-007/012 Study Teams. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009; 25:103 - 14; http://dx.doi.org/10.1089/aid.2008.0212; PMID: 19108693
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997; 336:86 - 91; http://dx.doi.org/10.1056/NEJM199701093360202; PMID: 8988885
   PubMed Web of Science ®Google Scholar
• McGill R. Variations of Box Plots. Am Stat 1978; 32:12 - 6
   Web of Science ®Google Scholar